1. Maintenance Therapy With Bortezomib and Dexamethasone for Transplant-ineligible Patients With Multiple Myeloma
- Author
-
Tomohiro Nakayama, Takashi Koike, Katsuhiro Miura, Masami Takei, Hiromichi Takahashi, Yoshihito Uchino, Masaru Nakagawa, Noriyoshi Iriyama, Yurika Noguchi, Kazuhide Iizuka, Yoshihiro Hatta, Takashi Hamada, Kazuya Kurihara, Tsutomu Yoshida, and Toshihide Endo
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Bortezomib ,medicine.disease ,Transplant ineligible ,Maintenance therapy ,Internal medicine ,Medicine ,business ,Multiple myeloma ,Dexamethasone ,medicine.drug ,Research Article - Abstract
Background/Aim: Here, we investigated whether bortezomib as a maintenance therapy affected outcomes in transplant-ineligible patients with multiple myeloma (MM). Patients and Methods: Following induction therapy with bortezomib, maintenance therapy with bortezomib (1.3 mg/m2) and dexamethasone (20 mg) was administered once or twice every 4 weeks until disease progression. The endpoints of this study were time to next treatment and overall survival. Results: Seventy-six newly diagnosed, transplant-ineligible patients were treated with a bortezomib-based regimen; 28 discontinued induction therapy, 27 did not receive maintenance therapy after induction therapy (the non-maintenance group), and 21 did (the maintenance group). In the three groups, the median times to the next required treatment were 3, 14, and 37 months, respectively. The 3-year overall survival rates were 55%, 69%, and 85%, respectively. There were no significant differences in patient characteristics between the non-maintenance and maintenance groups, except for poorer estimated glomerular filtration rates in the maintenance group. Conclusion: Bortezomib maintenance therapy may be a useful option for transplant-ineligible patients with MM.
- Published
- 2021